Back to Search
Start Over
Under-representation of Women as Proceduralists and Patients in TAVR and TMVr Procedures: Data, Implications and Proposed Solutions.
- Source :
-
European cardiology [Eur Cardiol] 2022 Dec 19; Vol. 17, pp. e27. Date of Electronic Publication: 2022 Dec 19 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Women are under-represented among transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVr) operators. This review assesses the representation of women as patients and as proceduralists and trial authors in major structural interventions. Women are under-represented as proceduralists in structural interventions: only 2% of TAVR operators and 1% of TMVr operators are women. Only 1.5% of authors in landmark clinical TAVR and TMVr trials are interventional cardiologists who are women (4/260). Significant under-representation and under-enrolment of women in landmark TAVR trials is evident: the calculated participation-to-prevalence ratio (PPR) is 0.73, and in TMVr trials, the PPR is 0.69. Under-representation of women is also evident in registry data (PPR = 0.84 for TAVR registries and for TMVr registries). In structural interventional cardiology, women are under-represented as proceduralists, trial participants and patients. This under-representation has the potential to affect the recruitment of women to randomised trials, subsequent guideline recommendations, selection for treatment, patient outcomes and sex-specific data analysis.<br />Competing Interests: Disclosure: SBu is a member of the ANZET (Australian and New Zealand Endovascular Therapeutics) meeting organising committee, her hospital’s ethics committee and a committee member of the Women as One Quality, Ethics and Equity Standards Committee. SZ reports consulting fees from Therapeutic Guidelines and Medtronic, and presentation honoraria from The Limbic, Boehringer Ingelheim and AstraZeneca. AC reports consulting fees from Abiomed and Shockwave Medical and honoraria from Boston Scientific, Biosensor and Abbott. MC reports research funding from Boston Scientific and Edwards Lifesciences and consulting fees from Medtronic, Abbott, Occlutech, Boston Scientific and Edwards Lifesciences. JS reports a scholarship from Monash University. SBa reports a grant from the Women as One Escalator Award 2021, speaker fees from Abbott Vascular and Menarini, is on the Shockwave Advisory Board and is Group Lead and Council Member of the British Cardiovascular Intervention Society. All other authors have no conflicts of interest to declare.<br /> (Copyright © 2022, Radcliffe Cardiology.)
Details
- Language :
- English
- ISSN :
- 1758-3764
- Volume :
- 17
- Database :
- MEDLINE
- Journal :
- European cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 36845217
- Full Text :
- https://doi.org/10.15420/ecr.2022.33